Bioethics News

Patient’s Death in Trial Raises Questions about Safety of Hemophilia Treatment Emicizumab

February 27, 2017

(Managed Care Magazine) – In a letter to the European Haemophilia Consortium, Roche has confirmed that one patient died in a phase 3 study of the bispecific antibody emicizumab. The death was considered to be unrelated to emicizumab, but, with the event following similar serious adverse reactions (SAEs) with other agents, it has added to questions about the safety of the experimental treatment.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.